In 2017, 6.4 million incident tuberculosis (TB) cases were reported globally, and an estimated 3.6 million went undiagnosed or were not notified ([@bib1]). Finding and treating these missing patients is a key target of the World Health Organization (WHO); this requires substantial international investment. It is critically important to protect this investment by providing effective treatment to every diagnosed patient.

The standard treatment for drug-sensitive TB lasts 6 months. Numerous studies have documented that patients struggle to adhere to the full course of therapy. An estimated 4--35% demonstrate poor adherence ([@bib2]--[@bib11]). Although various definitions have been used, poor adherence is associated with a reduced likelihood of sputum conversion ([@bib3]), greater risk of an unsuccessful treatment outcome ([@bib4], [@bib8], [@bib12]--[@bib15]), and the development of drug resistance ([@bib16]--[@bib19]). Nonadherence to TB treatment is associated with various factors: those that are patient related, derived from the healthcare provider--patient relationship, the regimen itself, and the healthcare system ([@bib20]).

In trials and observational studies, overly simplistic and non--evidence-based 80--90% adherence thresholds have traditionally been used to signify adequate adherence ([@bib12], [@bib21]--[@bib23]). Recently, however, the importance of highly accurate means of measuring adherence within clinical trials has been acknowledged by WHO as a key part of trial design ([@bib24]). Realistically, two core domains need to be considered when mapping adherence-persistence (time between first and last doses, capturing initiation and discontinuation) and dosing implementation (taking doses not as recommended; e.g., skipping weekends) ([@bib25]). These components constitute "therapeutic coverage": the proportion of time patients are exposed to efficacious drug concentrations ([@bib26]). Detailed mapping of adherence patterns has been missing from the TB literature to date.

Knowledge of how exactly patients with TB take their medications and predictors of when nonadherence is most likely to occur is critical for the directed design of interventions to improve adherence, to develop regimens that are more "forgiving" of nonadherence, and to help clinicians know when to intervene with nonadherent patients. Currently, the relative burden of suboptimal dosing implementation and discontinuation is unknown globally; interventions to address these two components of nonadherence may look quite different. This is a critical knowledge gap regarding reducing the burden of nonadherence, which is impeding the most cost-effective implementation of the WHO guidelines on digital adherence technologies for TB treatment ([@bib27]).

Using data collected from a trial of electronic reminders to improve medication adherence in China, we aimed to granularly describe how patients with TB take their medications and to determine if temporal factors were causally associated with missed doses to inform control efforts. Components of this study were reported previously in a conference abstract ([@bib28]).

Methods
=======

Parent Study and Study Population for Analysis
----------------------------------------------

The parent study, a pragmatic, cluster-randomized trial of electronic reminders to improve treatment adherence among patients with pulmonary TB in the People's Republic of China, from which these data are derived has been described before (*see* additional methods in the online supplement) ([@bib29]). Participants were enrolled in the study between June 1, 2011, and March 7, 2012. Only participants in the control arm of the trial were included in this cohort study to capture usual patterns of treatment adherence in the absence of an intervention (*see* additional methods in the online supplement).

Measuring and Defining Adherence to Treatment
---------------------------------------------

Adherence to each dose of treatment was documented by a medication monitor box (*see* additional methods in the online supplement). The box captured every date and time that it was opened; box opening did not necessarily mean that drugs were taken. Medication was dosed every other day (as per the National TB Program \[NTP\] standard at the time) for 90 doses over a 180-day period. If the box was opened at least once within each 2-day dosing window, this was recorded as adherence. The standard 6-month regimen for drug-sensitive TB was used (2 mo of isoniazid, rifampicin, ethambutol, and pyrazinamide, followed by 4 mo of isoniazid and rifampicin). Medication was not dosed in combination pills.

Nonadherence data from the monitor were coded and categorized as a dose missed because of suboptimal dosing implementation versus a dose missed because of permanent discontinuation, using accepted terminology as per Vrijens and colleagues ([@bib25]). "Discontinuation" was defined as ceasing to adhere to treatment and not recommencing both *1*) at any point during the 180-day period and *2*) after this period but before the end of the trial. Discontinuation is different from the programmatically defined term "lost to follow-up" (previously known as "default"), when either a patient's treatment is interrupted for two consecutive months or more or a patient does not start treatment. "Suboptimal dosing implementation" refers to all doses missed during the 180-day period, aside from those due to discontinuation. The term "suboptimal" is not intended to imply a judgment about the appropriate degree of adherence/type of adherence pattern required to achieve a positive treatment outcome; rather, it reflects an implementation level below 100% of doses taken.

Temporal Exposures and Potential Confounders
--------------------------------------------

The following temporal measures were calculated from the medication monitor data: *1*) day of the week, *2*) treatment month, *3*) whether the dose fell on a Chinese national holiday, and *4*) whether the patient was in the initiation or continuation phase of treatment (*see* additional methods in the online supplement). In addition, data were available for a series of potential confounders, all of which were self-reported at entry into the study. These included age, sex, marital status, education level, occupation, household income, type of medical insurance, registration status, and distance from home to TB clinic. The county/district in which the participant lived was grouped as broadly rural or urban.

Statistical Methods
-------------------

### Descriptive analyses

Analyses were undertaken using Stata 15 software (StataCorp), and graphs were plotted using Excel software (Microsoft Corp.). Adherence to treatment was described using the following summary measures: overall percentage of doses taken, average duration that a patient was receiving treatment before ceasing completely, percentage of participants achieving an 80% adherence threshold, and percentage of participants achieving a 90% threshold. To account for clustering, for each measure, the mean was calculated per county/district, and then the geometric mean was taken across the county/district values. Adherence over time, grouped by different percentage intervals, was graphically visualized using lasagna plots in which white indicates nonadherence ([@bib30]).

Line graphs were used to visualize nonadherence due to suboptimal dosing implementation versus permanent discontinuation from treatment for all participants in the study and by adherence levels in the initiation phase ([@bib31]). After plotting these graphs, we decided to separate suboptimal dosing implementation and discontinuation in the remaining analyses. The length and number of gaps in treatment due to suboptimal dosing implementation were described using scatterplots.

### Associations between temporal factors and suboptimal dosing implementation

We used mixed-effects logistic regression to examine the factors associated with nonadherence due to suboptimal dosing implementation, treating each dose as an observation and adjusting for clustering within a individual. We focused on temporal factors, including weekends, national holidays, and the initiation--continuation phase transition (Model 1) or treatment months (Model 2). Our methodology, including details of model selection through the use of directed acyclical graphs, determination of *a priori* confounders, and assessment of potential effect modification, is detailed elsewhere (*see* additional methods in the online supplement). The impact of using different confounder sets on our findings was explored through Models 1A--1F (*see* additional methods in the online supplement). Both approaches sought to address all confounding using different confounder sets to support the drawing of causal conclusions from observational data ([@bib32]). The potential presence of an interaction between the three temporal factors weekends, national holidays, and the initiation--continuation phase transition and *1*) county/district or *2*) distance from home to TB clinic was also explored using likelihood ratio tests (LRTs) (Models 1G and 1H).

### Associations between early suboptimal dosing implementation and time to discontinuation

Cox proportional hazards regression was used to assess whether early suboptimal dosing implementation, either in the initiation phase (Model 3) or in Month 1 (Model 4), was associated with time to discontinuation. Individuals who had discontinued in the initiation phase and Month 1 were excluded, respectively, to preserve the temporality of the association. Further details on adjustment for confounding and so forth are presented in the additional methods in the online supplement. We report the results of sensitivity analyses on the impact of confounding by county/district (Models 3F and 4F) and excluding individuals who discontinued during the last three doses of treatment (Models 3G and 4G). The potential presence of an interaction between early suboptimal dosing and *1*) county/district or *2*) distance from home to the TB clinic was also explored using LRTs.

Ethical Approval
----------------

The trial was approved by the ethics committees of the Chinese Center for Disease Control and Prevention (201008) and the London School of Hygiene & Tropical Medicine (5704). All participants provided written consent before inclusion in the trial.

Results
=======

Characteristics of the Study Population
---------------------------------------

Of the 1,104 individuals randomized to the control arm of the trial, 209 (18.9%) had technical issues with the medication monitor because of power outage problems, as indicated by the box resetting the date to a baseline value (*see* Figure E1 in the online supplement). A further 10.4% of patients (*n* = 115) were excluded because events such as hospitalization for more than 3 days removed the potential for treatment to be monitored for the entire period. Thus, data of 780 (70.7%) patients were available for analysis. A comparison of the included and excluded patients revealed similarity in terms of baseline characteristics, except for county/district and distance from home to the TB clinic (Table E1).

The baseline characteristics of participants are presented in [Table 1](#tbl1){ref-type="table"}. Individuals were generally male (*n* = 535; 68.6%). More than half were under the age of 50 years (*n* = 525; 67.3%). Farming was the largest occupation (*n* = 384; 49.2%), with 516 (66.2%) individuals living in counties/districts deemed rural and 500 (64.1%) ensured through rural cooperatives.

###### 

Baseline characteristics and unadjusted analyses of factors associated with nonadherence due to suboptimal dosing implementation or discontinuation

  Exposure Variables                                              Overall   Analysis of Suboptimal Dosing Implementation   Analysis of Discontinuation                                                                      
  -------------------------------------------------------------- --------- ---------------------------------------------- ----------------------------- ------- ------- ------ ------------------- -------- ----- -------------------
  Overall                                                           780                        100.0                                 62,893              100.0   9,487   15.1          ---          62,396   235          ---
  Sex                                                                                                                                                                                                                       
   Female                                                           245                         31.4                                 19,804              31.5    2,683   13.5       Baseline        19,649   161       Baseline
   Male                                                             535                         68.6                                 43,089              68.5    6,804   15.8   1.20 (0.99--1.45)   42,747   74    1.00 (0.76--1.32)
  Age category, yr                                                                                                                                                                                                          
   \<30                                                             230                         29.5                                 18,305              29.1    2,837   15.5       Baseline        18,157   69        Baseline
   30--39                                                           128                         16.4                                 10,099              16.1    1,315   13.0   1.01 (0.95--1.08)   10,021   44    0.95 (0.87--1.04)
   40--49                                                           167                         21.4                                 13,518              21.5    2,077   15.4                       13,422   56             
   50--59                                                           136                         17.4                                 11,117              17.7    1,712   15.4                       11,023   35             
   60+                                                              119                         15.3                                  9,854              15.7    1,546   15.7                       9,773    31             
  Occupation                                                                                                                                                                                                                
   Student                                                          32                          4.1                                   2,529               4.0     428    16.9   1.01 (0.64--1.58)   2,512    13    1.34 (0.76--2.37)
   Worker                                                           74                          9.5                                   6,102               9.7     722    11.8   0.61 (0.45--0.84)   6,048    17    0.69 (0.42--1.15)
   Migrant worker                                                   74                          9.5                                   6,167               9.8     815    13.2   0.76 (0.55--1.03)   6,115    17    0.68 (0.41--1.13)
   Farmer                                                           384                         49.2                                 30,763              48.9    5,347   17.4       Baseline        30,523   122       Baseline
   Unemployed/houseworker                                           63                          8.1                                   5,207               8.3     624    12.0   0.60 (0.43--0.84)   5,165    17    0.81 (0.49--1.35)
   Other                                                            153                         19.6                                 12,125              19.3    1,551   12.8   0.68 (0.53--0.86)   12,033   49    1.02 (0.73--1.42)
  Education level                                                                                                                                                                                                           
   Illiterate                                                       60                          7.7                                   4,595               7.3     858    18.7   1.38 (0.92--2.07)   4,557    20    1.43 (0.79--2.59)
   Lower middle school                                              494                         63.3                                 39,999              63.6    6,254   15.6   1.03 (0.78--1.35)   39,692   154   1.25 (0.82--1.93)
   Upper middle school                                              130                         16.7                                 10,571              16.8    1,216   11.5   0.73 (0.52--1.02)   10,484   37    1.13 (0.68--1.89)
   University or more                                               96                          12.3                                  7,728              12.3    1,159   15.0       Baseline        7,663    24        Baseline
  Total household income in last calendar yr (RMB)                                                                                                                                                                          
   ≥20,000                                                          446                         57.2                                 36,044              57.3    4,994   13.9       Baseline        35,754   131       Baseline
   \<20,000                                                         334                         42.8                                 26,849              42.7    4,493   16.7   1.31 (1.10--1.57)   26,642   104   1.07 (0.83--1.38)
  Medical insurance                                                                                                                                                                                                         
   Rural cooperative                                                500                         64.1                                 40,583              64.5    6,604   16.3   1.23 (0.96--1.57)   40,261   146   0.65 (0.48--0.89)
   Urban workers                                                    92                          11.8                                  7,843              12.5     946    12.1   0.86 (0.61--1.20)   7,773    18    0.40 (0.24--0.69)
   No insurance                                                     132                         16.9                                  9,855              15.7    1,350   13.7       Baseline        9,786    53        Baseline
   Other                                                            56                          7.2                                   4,612               7.3     587    12.7   0.95 (0.64--1.41)   4,576    18    0.71 (0.42--1.21)
  Marital status                                                                                                                                                                                                            
   First marriage                                                   551                         70.6                                 45,024              71.6    6,707   14.9       Baseline        44,665   161       Baseline
   Unmarried                                                        184                         23.6                                 14,421              22.9    2,194   15.2   1.02 (0.82--1.26)   14,305   57    1.11 (0.82--1.50)
   Other                                                            45                          5.8                                   3,448               5.5     586    17.0   1.15 (0.78--1.69)   3,426    17    1.43 (0.87--2.35)
  County                                                                                                                                                                                                                    
   Baiquan                                                          100                         12.8                                  7,629              12.1    1,926   25.2       Baseline        7,581    46        Baseline
   Yilan                                                            103                         13.2                                  8,683              13.8    1,113   12.8   0.40 (0.29--0.56)   8,605    15    0.26 (0.15--0.47)
   Rugao                                                            78                          10.0                                  6,366              10.1     844    13.3   0.39 (0.27--0.56)   6,310    21    0.52 (0.31--0.87)
   Jianhu                                                           80                          10.3                                  6,938              11.0    1,270   18.3   0.60 (0.42--0.86)   6,878    13    0.29 (0.16--0.54)
   Miluo                                                            85                          10.9                                  6,961              11.1    1,131   16.2   0.55 (0.39--0.78)   6,905    24    0.55 (0.34--0.90)
   Yueyanglou                                                       81                          10.4                                  5,893               9.4     718    12.2   0.35 (0.24--0.50)   5,856    42    1.21 (0.79--1.83)
   Fengjie                                                          70                          9.0                                   5,115               8.1     684    13.4   0.39 (0.27--0.56)   5,088    40    1.34 (0.88--2.04)
   Shapingba                                                        79                          10.1                                  6,311              10.0     915    14.5   0.49 (0.34--0.70)   6,258    18    0.45 (0.26--0.78)
   Jiangbei                                                         104                         13.3                                  8,997              14.3     886    9.8    0.29 (0.21--0.40)   8,915    16    0.27 (0.16--0.49)
  Rural/urban                                                                                                                                                                                                               
   Rural                                                            516                         66.2                                 41,692              66.3    6,968   16.7       Baseline        41,367   159       Baseline
   Urban                                                            264                         33.8                                 21,201              33.7    2,519   11.9   0.67 (0.55--0.81)   21,029   76    0.94 (0.71--1.23)
  Residence                                                                                                                                                                                                                 
   Living in place of household registration                        658                         84.4                                 53,187              84.6    8,191   15.4       Baseline        52,768   198       Baseline
   Not living in place of household registration                    122                         15.6                                  9,706              15.4    1,296   13.4   0.80 (0.62--1.03)   9,628    37    1.03 (0.72--1.46)
  Distance from home to local TB clinic, km                                                                                                                                                                                 
   \<10                                                             188                         24.1                                 15,984              25.4    2,255   14.1       Baseline        15,847   37        Baseline
   10--19                                                           191                         24.5                                 15,185              24.1    2,199   14.5   1.05 (0.99--1.12)   15,065   63    1.14 (1.04--1.24)
   20--29                                                           118                         15.1                                  9,596              15.3    1,451   15.1                       9,524    40           ---
   30--39                                                           149                         19.1                                 11,802              18.8    1,782   15.1                       11,714   49           ---
   ≥40                                                              134                         17.2                                 10,326              16.4    1,800   17.4                       10,246   46           ---
  Day                                                                                                                                                                             *P* \< 0.001                              
   Sunday                                                           ---                         ---                                   9,009              14.3    1,516   16.8       Baseline         ---     ---          ---
   Monday                                                           ---                         ---                                   8,997              14.3    1,301   14.5   0.81 (0.74--0.89)    ---     ---          ---
   Tuesday                                                          ---                         ---                                   8,939              14.2    1,344   15.0   0.84 (0.77--0.92)    ---     ---          ---
   Wednesday                                                        ---                         ---                                   9,004              14.3    1,315   14.6   0.83 (0.76--0.91)    ---     ---          ---
   Thursday                                                         ---                         ---                                   8,895              14.1    1,426   16.0   0.93 (0.85--1.01)    ---     ---          ---
   Friday                                                           ---                         ---                                   9,275              14.7    1,251   13.5   0.74 (0.68--0.81)    ---     ---          ---
   Saturday                                                         ---                         ---                                   8,774              14.0    1,334   15.2   0.87 (0.80--0.95)    ---     ---          ---
  Weekend                                                                                                                                                                         *P* \< 0.001                              
   Weekday                                                          ---                         ---                                  45,110              71.7    6,637   14.7       Baseline         ---     ---          ---
   Weekend                                                          ---                         ---                                  17,783              28.3    2,850   16.0   1.13 (1.07--1.19)    ---     ---          ---
  Month                                                                                                                                                                           *P* \< 0.001                              
   1                                                                ---                         ---                                  11,687              18.6     789    6.8        Baseline         ---     ---          ---
   2                                                                ---                         ---                                  11,298              18.0    1,383   12.2   2.92 (2.60--3.28)    ---     ---          ---
   3                                                                ---                         ---                                  10,800              17.2    1,857   17.2   5.35 (4.66--6.13)    ---     ---          ---
   4                                                                ---                         ---                                  10,314              16.4    1,843   17.9   5.78 (4.91--6.81)    ---     ---          ---
   5                                                                ---                         ---                                   9,770              15.5    1,839   18.8   6.31 (5.21--7.65)    ---     ---          ---
   6                                                                ---                         ---                                   9,024              14.3    1,776   19.7   6.26 (5.01--7.83)    ---     ---          ---
  National holidays                                                                                                                                                               *P* \< 0.001                              
   No                                                               ---                         ---                                  58,018              92.2    8,487   14.6       Baseline         ---     ---          ---
   Yes                                                              ---                         ---                                   4,875               7.8    1,000   20.5   1.62 (1.49--1.75)    ---     ---          ---
  Phase                                                                                                                                                                           *P* \< 0.001                              
   Initiation                                                       ---                         ---                                  22,985              36.5    2,172   9.4        Baseline         ---     ---          ---
   Continuation                                                     ---                         ---                                  39,908              63.5    7,315   18.3   3.09 (2.70--3.54)    ---     ---          ---
  Initiation phase adherence[\*](#tblfn1){ref-type="table-fn"}                                                                                                                                                        *P* = 0.003
   ≥90%                                                             ---                         ---                                    ---                ---     ---    ---           ---          47,419   137       Baseline
   80--90%                                                          ---                         ---                                    ---                ---     ---    ---           ---          7,373    22    1.05 (0.67--1.64)
   \<80%                                                            ---                         ---                                    ---                ---     ---    ---           ---          6,819    36    1.98 (1.37--2.86)
  Month 1 adherence[^†^](#tblfn2){ref-type="table-fn"}                                                                                                                                                                *P* = 0.003
   ≥90%                                                             ---                         ---                                    ---                ---     ---    ---           ---          51,106   171       Baseline
   80--90%                                                          ---                         ---                                    ---                ---     ---    ---           ---          7,471    34    1.39 (0.96--2.00)
   \<80%                                                            ---                         ---                                    ---                ---     ---    ---           ---          3,757    25    2.10 (1.38--3.19)

*Definition of abbreviations*: --- = not applicable; CI = confidence interval; HR = hazard ratio; OR = odds ratio; RMB = renminbi; TB = tuberculosis.

Leftmost data columns: baseline characteristics of the 780 individuals from the control arm of the original trial. Middle data columns: unadjusted mixed-effects logistic regression for the 780 individuals included in the analysis of suboptimal dosing implementation. Each model was adjusted for clustering within a patient. Age and distance to TB clinic were modeled as linear variables. Random effects were modeled on the initiation--continuation phase and month variables within the relevant unadjusted model. Rightmost data columns: unadjusted Cox regression for the 780 individuals included in the analysis of discontinuation. Age and distance to TB clinic were modeled as linear variables. Analysis time documents the time at risk and under observation. All columns: No data were missing for any of the variables.

A total of 740 individuals were included in the initiation phase adherence model; this exposure variable documents nonadherence due to suboptimal dosing implementation only.

A total of 775 individuals were included in the Month 1 adherence model; this exposure variable documents nonadherence due to suboptimal dosing implementation only.

Summary Measures of Overall Adherence
-------------------------------------

Across all 780 study participants, 70,200 doses were scheduled during the 180-day period; 16,794 of these were missed (23.9%). The geometric mean number of doses taken was 68/90 (75.6%). The geometric mean duration of receiving treatment was 80 doses (i.e., 160 d) before discontinuation.

Overall Adherence over Time
---------------------------

Lasagna plots of adherence over time demonstrated the distribution of participants in 20% adherence intervals, with 473 (60.6%) of 780 in the highest category of greater than or equal to 80% to 100% adherent ([Figure 1](#fig1){ref-type="fig"}). A clear "staggered" pattern was observed in the lowest categories that corresponded to dropoffs in adherence with each passing month (15 doses; 30 d). Although there was a reduction in adherence over time, erratic nonadherence (suboptimal dosing implementation) was observed throughout the treatment period.

![Lasagna plot of adherence. Each patient of the 780 participants in the control arm of the original trial is represented by a row in the figure; white indicates a dose that has not been taken. Adherence was calculated as a percentage of the 90 doses taken over the 180-day period and then grouped into 20% adherence intervals. Rows are colored by adherence group. Numbers in brackets indicate the number of individuals within each 20% adherence interval. Reprinted by permission from Reference [@bib28].](AnnalsATS.201905-394OC_f1){#fig1}

The relative importance of nonadherence due to the permanent discontinuation of treatment versus suboptimal dosing implementation is shown in [Figure 2A](#fig2){ref-type="fig"}. Of the 16,794 missed doses, 9,487 were due to suboptimal dosing implementation (56.5%), and the remainder were due to discontinuation. The impact of discontinuation was demonstrably stronger over time. By the end of Month 2, 5.1% of individuals had discontinued treatment; this figure was 14.4% by the end of Month 4 and continued to increase during the last two months until it reached 36.3% at the end of the 180-day period. The latter figure reflects the fact that discontinuation captures treatment cessation without recommencement at any time point, including cessation at the last (90th) dose. When the 121 participants with less than 80% adherence in the initiation phase were examined separately, they demonstrated sharp and sustained reductions in adherence due to both discontinuation and suboptimal dosing implementation ([Figure 2C](#fig2){ref-type="fig"}).

![Relative contribution of discontinuation and suboptimal dosing implementation to nonadherence over time. Nonadherence due to discontinuation (ceasing treatment and not recommencing; dark gray) versus suboptimal dosing implementation (sporadic missed doses; light gray) over time in (*A*) the 780 control arm patients from the original trial, (*B*) the 659 patients who displayed greater than or equal to 80% adherence during the initiation phase, and (*C*) the 121 patients who displayed less than 80% adherence in the initiation phase. Discontinuation is ceasing treatment at any stage, including only for the 90th dose. If, after the 90th dose, another dose was taken before the end of the trial, the patient is not recorded as having discontinued. Discontinuation is not the same as programmatically defined loss to follow-up/default. Figure style adapted from Reference [@bib31].](AnnalsATS.201905-394OC_f2){#fig2}

Gaps in Adherence (Suboptimal Dosing Implementation)
----------------------------------------------------

Suboptimal dosing implementation was demonstrated by 748 (95.9%) of 780 participants; that is, they displayed at least one gap in their treatment of one dose or more that was not due to discontinuation. Overall, a total of 4,677 gaps were recorded, of which 71.4% (3,337 of 4,677) were for one dose only. The population median of the median gap length per participant was 1, and the interquartile range was 1--1 ([Figure 3A](#fig3){ref-type="fig"}). When the maximum gap length per participant was examined, the median across the population was two doses (interquartile range, 1--6) ([Figure 3B](#fig3){ref-type="fig"}). Of the 780 individuals, 368 (47.2%) had at least one gap of three doses (roughly 1 wk) or more, and 176 (22.6%) had at least one gap of seven doses (roughly 2 wk) or more.

![Gaps in adherence. Gaps during the 90-dose medication period among the 748 participants who displayed suboptimal dosing implementation. Number of gaps per participant of any length plotted against (*A*) the median gap length per participant and (*B*) the maximum gap length per participant.](AnnalsATS.201905-394OC_f3){#fig3}

Associations between Suboptimal Dosing Implementation and Temporal Factors
--------------------------------------------------------------------------

Our analysis of suboptimal dosing implementation and temporal factors was composed of 780 patients and 62,893 dose observations ([Table 1](#tbl1){ref-type="table"}). In unadjusted analyses, a strong association was seen between the initiation--continuation phase transition and suboptimal dosing implementation. The continuation phase was associated with triple the odds of suboptimal dosing implementation (odds ratio, 3.09 \[95% confidence interval, 2.70--3.54\]). This mirrors the month-by-month findings, in which suboptimal dosing implementation increased from 6.8% of doses in Treatment Month 1 to 19.7% in Treatment Month 6. Sunday was associated with greater suboptimal dosing implementation than the other days of the week (*P* \< 0.001). Compared with weekdays, weekends were associated with a small increase in the odds of suboptimal dosing implementation (1.13 \[1.07--1.19\]). National holidays were associated with a larger increase in odds of suboptimal dosing implementation (1.62 \[1.49--1.75\]; 14.6--20.5%).

In an adjusted model controlling for age as a linear variable, as well as sex and urban versus rural setting, and with a random effect on the initiation--continuation variable (LRT *P* \< 0.001), all three temporal variables were associated with greater odds of suboptimal dosing implementation (weekends, 1.14 \[1.08--1.20\]; national holiday, 1.52 \[1.39--1.65\]; initiation--continuation transition, 3.07 \[2.68--3.51\]) (Model 1). There was no evidence for interactions between the initiation--continuation transition and national holidays (LRT *P* = 0.97) or weekends (LRT *P* = 0.07). These findings were robust to adjustment for different combinations of confounders (Table E2, Models 1A--1F).

Tests for interaction were performed between the three temporal factors and county/district or distance. For distance, the LRT *P* values for the initiation--continuation phase transition, holidays, and weekends were 0.52, 0.97, and 0.91, respectively. For county/district, the LRT *P* values for the initiation--continuation phase transition, holidays, and weekends were 0.01, less than 0.001, and 0.79, respectively. We thus undertook stratified analyses by county/district of the relationship between suboptimal implementation and *1*) the initiation--continuation phase transition (Table E3, Model 1G) or *2*) holidays (Table E4, Model 1H). Although the magnitude of the relationship between these two temporal factors and suboptimal implementation was altered by county, the direction of effect was the same in all instances, barring one instance in which the confidence interval crossed the null (Baiquan County, Model 1H; 0.94 \[0.75--1.18\]).

Given the striking initiation--continuation phase effect found in these models, but also the more gradual pattern of reducing adherence demonstrated in [Figure 1](#fig1){ref-type="fig"}, the association between treatment month and suboptimal dosing implementation was assessed. A random effect was included on the treatment month (LRT *P* \< 0.001), which was treated as a categorical variable. An interaction was documented between treatment month and national holidays (LRT *P* = 0.01), but the statistical evidence was less certain for an interaction between treatment month and weekends (LRT *P* = 0.06).

Within a model containing the treatment month--national holiday interaction (Model 2), the association between weekends and the odds of nonadherence due to suboptimal dosing implementation changed little from Model 1 (1.14 \[1.08--1.20\]). From month to month, the likelihood of suboptimal dosing implementation approximately increased and was particularly pronounced for doses that fell on national holidays ([Table 2](#tbl2){ref-type="table"}). A dose falling on a national holiday was positively associated with suboptimal dosing implementation, with the largest increase in odds in the last month of treatment, but no clear trend from month to month ([Table 2](#tbl2){ref-type="table"}).

###### 

Adjusted odds ratios for the association between suboptimal dosing implementation and treatment month, stratified by national holidays, or national holidays, stratified by treatment month

                                                      National Holidays  
  -------------------------------------------------- ------------------- ---------------------
  Treatment month, stratified by national holidays                                  
   Treatment month                                                                  
    1                                                     Baseline             Baseline
    2                                                 2.87 (2.55--3.23)    3.32 (2.15--5.15)
    3                                                 5.23 (4.55--6.01)    5.82 (3.81--8.90)
    4                                                 5.58 (4.72--6.58)   7.34 (4.76--11.31)
    5                                                 6.23 (5.13--7.57)   6.45 (4.11--10.12)
    6                                                 5.90 (4.71--7.40)   10.01 (6.27--15.98)
  National holidays, stratified by treatment month                                  
   Treatment month                                                                  
    1                                                     Baseline         1.25 (0.85--1.84)
    2                                                     Baseline         1.45 (1.15--1.82)
    3                                                     Baseline         1.39 (1.16--1.67)
    4                                                     Baseline         1.64 (1.36--1.98)
    5                                                     Baseline         1.29 (1.06--1.58)
    6                                                     Baseline         2.12 (1.71--2.62)

The table shows the results of adjusted regression of the association between nonadherence due to suboptimal dosing implementation and treatment month, stratified by national holidays (top rows), or national holidays, stratified by treatment month (bottom rows). Model 2: A total of 62,893 doses from 780 individuals from the control arm of the original trial are included. The stratum-specific odds ratios are adjusted for weekends, age, sex, and rural versus urban setting. Random effects are modeled on the month variable. Age is modeled as a linear variable. Results per cell are presented as odds ratio (95% confidence interval).

Associations between Time to Discontinuation and Early Suboptimal Dosing Implementation
---------------------------------------------------------------------------------------

Among the individuals included in the study, 109 were found to stop treatment without recommencing within the 90-dose period but to later recommence before the end of the trial. The latest dose taken was at 254 days. These individuals were not classified as discontinuing. Patients who discontinued during the relevant implementation period were excluded to preserve temporality within any associations. Thus, 740 patients contributed to an analysis of discontinuation and suboptimal dosing implementation in the initiation phase, and 775 contributed when suboptimal dosing implementation in Month 1 was instead considered ([Table 1](#tbl1){ref-type="table"}).

In unadjusted analyses, increased suboptimal dosing implementation in the initiation phase and Month 1 was associated with an increase in the likelihood of discontinuation ([Table 1](#tbl1){ref-type="table"}). These findings were robust in an adjusted analysis ([Table 3](#tbl3){ref-type="table"}). The impact of greater than or equal to 80% to less than 90% adherence versus greater than or equal to 90% adherence was less certain for the initiation phase analysis (Model 3), but it was more suggestive of a dose--response association in the Month 1 analysis (Model 4). Considering different confounder sets, these models were robust to adjustment for a fixed effect for county/district rather than urban/rural (Table E5, Models 3F and 4F). When the 52 individuals who discontinued from dose 87 onward were excluded, our effect estimates increased for both the initiation phase and Month 1 analyses (Table E5, Models 3G and 4G). Tests for interaction between early suboptimal dosing implementation and county/district revealed no evidence for an effect (LRT *P* = 0.19).

###### 

Adjusted Cox regression models of the association between early suboptimal dosing implementation and discontinuation

  Temporal Factor                Hazard Ratio (95% CI)
  ----------------------------- -----------------------
  Model 3                                   
   Initiation phase adherence         *P* = 0.004
    ≥90%                               Baseline
    80% to \<90%                   1.04 (0.66--1.63)
    \<80%                          1.97 (1.36--2.85)
  Model 4                                   
   Month 1 adherence                  *P* = 0.004
    ≥90%                               Baseline
    80% to \<90%                   1.37 (0.95--1.99)
    \<80%                          2.06 (1.35--3.15)

*Definition of abbreviation*: CI = confidence interval.

Model 3 examines the association between nonadherence in the initiation phase due to suboptimal dosing implementation and discontinuation, adjusting for age, sex, and rural versus urban setting. It excludes individuals who discontinued in the initiation phase, leaving 740. Model 4 examines the association between nonadherence in Month 1 due to suboptimal dosing implementation and discontinuation, adjusting for age, sex, and rural versus urban setting. It excludes individuals who discontinued during Month 1, leaving 775. Age was modeled as a linear variable.

Discussion
==========

Our analysis of adherence, both suboptimal dosing implementation and discontinuation, among patients with pulmonary TB in China provides the first detailed description of how doses are missed over a 6-month treatment period. We found that participants took 76% of their doses; 61% took 80% or more. The use of simple percentage thresholds, however, masks important variation in the patterns of missed doses over time.

Of all missed doses, 43% were due to discontinuation. A steady increase was observed in nonadherence due to both suboptimal dosing implementation and discontinuation over time. At 2 months, 5.1% of participants had discontinued their medication; 14.4% had discontinued at 4 months, and 36.3% had discontinued by the end of the 180-day period. During the intensive phase of treatment (the first 2 mo), suboptimal dosing implementation accounted for the majority of nonadherence. Of the 19% of patients who were nonadherent at the end of the intensive phase, discontinuation accounted for 27% of the nonadherence, and suboptimal dosing implementation accounted for the remainder. During the continuation phase (Months 3--6), the odds of suboptimal dosing implementation were three times higher than during the intensive phase, but the percentage of patients with suboptimal dosing implementation remained stable at 17--20%. However, the percentage of those who discontinued treatment continued to accumulate, and by the fifth month, discontinuation accounted for 52% of all nonadherence.

We identified an important association between suboptimal dosing implementation early in the course of treatment and subsequent discontinuation. Suboptimal dosing implementation in the first month or overall initiation phase (Months 1 and 2) was associated with higher discontinuation rates. Across participants, 96% demonstrated suboptimal dosing implementation; approximately three-fourths of gaps were for one dose only. Nevertheless, 47% of individuals had potentially clinically important gaps of three consecutive doses or more, and 23% had potentially clinically important gaps of seven consecutive doses (about 2 wk) or more. The odds of suboptimal dosing implementation were higher on national holidays (odds ratio, 1.52).

The findings of this study provide several insights into how drug-sensitive TB treatment can be improved. First, NTPs should take seriously the problem of nonadherence to treatment, which is underrecognized. In this study, a high percentage of patients had gaps of 1 week or more in their treatment due to suboptimal dosing implementation. If these gaps are not recognized and treatment is not adjusted accordingly, then long-term relapse-free cure of these patients may be compromised. NTPs should place a much higher priority on improving adherence during treatment and not simply focus on ensuring completion.

Second, this study identified the importance of early adherence. Adherence worsened over the course of treatment, especially after the shift into the continuation phase. We also found an association between discontinuation and early suboptimal dosing implementation. Thus, improving adherence early in the course of treatment may be important to prevent later nonadherence.

Third, this study highlights the importance of granular adherence data on individual patients. Early identification of individuals with poor adherence or who discontinue would improve the likelihood of success of adherence-promoting interventions. Identification of such individuals could result in the initiation of differentiated care, which would include more tailored adherence support for these patients. The design of such behavioral interventions should take into account data on the types of nonadherence displayed by the target population and their causes. For example, plans to support medication adherence may need to be generated proactively with patients before holiday periods, when travel to different locations may generate greater concern about stigma and result in missed doses. In order to check for improvement, adherence should also be monitored after such interventions are deployed. Digital technologies to record adherence, such as by using pill bottle opening as a surrogate for medication intake, have been available for many years and are starting to be rolled out globally, despite operational barriers such as cost ([@bib33]). Such technologies, however, provide an opportunity to monitor TB treatment adherence in individual patients on a large scale ([@bib33]).

Fourth, these results lend support to the development of shorter treatment regimens, which may avoid the adherence dropoff later in treatment that is currently observed. Such regimens have not yet demonstrated noninferiority ([@bib34]--[@bib36]); however, they will likely increase the importance of each individual dose in ensuring cure. Retrieving patients who default from treatment is a large financial burden on NTPs; this could also be reduced with shorter regimens that result in less discontinuation. We also highlight the value of examining discontinuation of treatment, rather than programmatically defined loss to follow-up/default, in terms of capturing effective drug exposure.

Overall, previous studies have provided the initial basis of a link between different adherence patterns and treatment outcomes in drug-sensitive disease ([@bib2]--[@bib9], [@bib11]). For example, missing 8--16% of doses has been associated with 25 times the odds of remaining sputum positive ([@bib3]), adhering below a 90% threshold with 5.9 times the rate of an unfavorable outcome ([@bib15]), adhering below a 75% threshold with 3.2 times the odds of recurrence ([@bib14]), adhering below a 90% threshold with 3.4 times the odds of mortality ([@bib4]), and "irregular" drug taking such that treatment had to be extended with 2.5 times increased odds of relapse ([@bib8]). Conversely, a regimen simulating less than 67% adherence had no impact on recurrence ([@bib37]). In addition, previous studies have documented a 17% additional hazard per month of acquired drug resistance if adherence is less than 80% ([@bib19]), or 19.7 times the odds with half-month gaps, nonengagement, or less than 80% adherence ([@bib16]). This association is not simple; particularly poor adherence may exert little selective pressure ([@bib17]). In drug-resistant disease, there is a smaller but less contradictory evidence base in terms of the implications of nonadherence: Long interruptions and less than 80% to 90% adherence have been associated with poorer outcomes ([@bib17], [@bib19], [@bib38], [@bib39]). What these studies lack, which potentially explains their conflicting findings, is a granular exploration of how nonadherence influences treatment outcomes using reliable sources of adherence data ([@bib23]). Our study indicates that poor adherence is complicated and heterogeneous; future studies will require granular dose-by-dose data to properly assess the nonadherence--outcome relationship. Future studies should collect detailed adherence data, moving away from monthly self-reported information and chart reviews, to ascertain how they correlate to therapeutic coverage, pharmacokinetics (TB drugs with a short half-life are predicted to be less forgiving), sputum conversion rates, treatment outcomes ([@bib40]), relapse (the gold standard outcome measure), and the development of drug resistance.

This is the most detailed analysis to date of treatment adherence in TB that makes use of exceptionally granular adherence data. It does, however, have its limitations. Whether drug intake was supported (e.g., observed by a family member) or self-administered was not documented, potentially leaving residual confounding. Opening the medication monitor box does not necessarily mean that drugs were taken, although a validation study has indicated high correlation with urine rifampicin concentrations ([@bib41]). Given that each dose could have been taken during a 2-day period, nondifferential misclassification of the temporal exposure variables may have occurred, biasing effect estimates toward the null. Fixed-dose combination pills were not used, so it is possible that nonadherence was underestimated per drug, because individuals may have chosen not to take all of their pills per dose. The exclusion of participants for whom a whole dosing history was not available may have resulted in selection bias, because excluded participants differed from included participants in terms of the county/district in which they lived and their distance from home to their local TB clinic. On the basis of tests for interaction, it seems unlikely, however, that temporal factors (the focus of our analysis) are systematically differently associated with adherence across different levels of these variables. Data were missing on participants' personal holidays, which could bias the effect size toward the null. Furthermore, part of the national holiday effect could represent individuals not transporting their monitor boxes with them when they travel, but nevertheless taking their medication. Sociobehavioral data on factors associated with nonadherence, such as stigma, were not collected, potentially resulting in residual confounding. Finally, participants may have been aware that they would be less likely to have taken their drugs on weekends and thus switched their doses from weekends to weekdays to avoid nonadherence. This is a function of the every-other-day dosing of the regimen and would result in an overemphasized effect size.

Four key factors in our study affect generalizability: This was a *1*) single-country dataset of *2*) patients with pulmonary TB *3*) enrolled in a trial who *4*) took their drugs every other day. Being enrolled in a trial is believed to boost adherence, and the individuals who consent to participate are often more likely to be adherent; adherence data from observational studies globally are therefore also needed ([@bib42]--[@bib44]). We thus recommend future studies using granular adherence data from observational studies undertaken in other nations.

Conclusions
-----------

In conclusion, we demonstrate how nonadherence to TB treatment is a complex issue that needs to be taken seriously. Adherence worsens over the course of treatment, but early-stage interventions (when suboptimal dosing implementation is first detected) may prevent later discontinuation. For such interventions to be accurately targeted to the patients most in need, individual-level adherence data are required on a large scale. Shorter TB treatment regimens may reduce the impact of worsening adherence over the treatment course.
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